Prevention of Postpartum Hemorrhage With Tranexamic Acid
Status:
Active, not recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Postpartum hemorrhage is a significant contributor to maternal morbidity and mortality and is
worldwide. TXA has recently been proven to reduce mortality when given to women in setting of
diagnosed PPH. US obstetricians and anesthesiologists are hesitant to use TXA in the
peripartum period especially for prevention of PPH due to uncertainty of an optimal dose and
safety profile. The purpose of this study is to characterize the pharmacokinetics of TXA when
given prophylactically at time of delivery. In addition investigators will determine the
pharmacodynamics of TXA in the peripartum period.
Phase:
Phase 2
Details
Lead Sponsor:
Homa Ahmadzia
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH)